Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

13G Filing: Matrix Capital Management and Adaptimmune Therapeutics PLC – ADR (ADAP)

Published on September 12, 2017 at 11:42 am by Insider Monkey Staff in Hedge Funds

Page 1 of 8

Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP): David Goel And Paul Ferri’s Matrix Capital Management filed an amended 13D.

You can check out Matrix Capital Management’s latest holdings and filings here.

Please follow Matrix Capital Management (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Matrix Capital Management or update its stock holdings.

Follow David E. Goel And Paul J. Ferri's Matrix Capital Management

We may use your email to send marketing emails about our services. Click here to read our privacy policy.

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name	Sole Voting Power	Shared Voting Power	Sole Dispositive Power	Shared Dispositive Power	Aggregate Amount Owned Power	Percent of Class
Matrix Capital Management Company		72,261,066		72,261,066	72,261,066	12.9%
David E. Goel		72,261,066		72,261,066	72,261,066	12.9%

Follow David E. Goel And Paul J. Ferri's Matrix Capital Management

We may use your email to send marketing emails about our services. Click here to read our privacy policy.

Page 1 of 8 – SEC Filing

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


SCHEDULE 13G


Under the Securities Exchange Act of 1934

(Amendment No. )*

Adaptimmune Therapeutics PLC
(Name of Issuer)

Ordinary Shares, par value £0.001
(Title of Class of Securities)

00653A107**
(CUSIP Number)

August 31, 2017
(Date of event which requires filing of this statement)


Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:

x	Rule 13d-1(b)
¨	Rule 13d-1(c)
¨	Rule 13d-1(d)

(Page 1 of 8 Pages)

______________________________

* The remainder of this cover page shall
be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any
subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

** There is no CUSIP number assigned to
the Ordinary Shares. CUSIP number 00653A107 has been assigned to the American Depositary Shares (“ADSs“) of the
Company. Each ADS represents 6 Ordinary Shares.

The information required in the remainder
of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of
1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).

Follow Adaptimmune Therapeutics Plc (NASDAQ:ADAP)

Follow Adaptimmune Therapeutics Plc (NASDAQ:ADAP)

We may use your email to send marketing emails about our services. Click here to read our privacy policy.

Page 1 of 8

NASDAQ:ADAP SEC 13G Filing Matrix Capital Management Adaptimmune Therapeutics PLC - ADR (ADAP)